文章摘要

文章信息/Info

Title:: Prevention of renal dysfunction in patients with heart failure: new understanding and research progress

作者:: 刘琳琳¹; 黎辉²; (1.哈尔滨医科大学大庆校区；
2.大庆油田总医院心内科，黑龙江大庆 163000）

Author(s):: LIU Lin Lin¹; LI Hui²; (1.Daqing Branch of Harbin Medical University;
2.Department of Cardiology, General Hospital of Daqing Oil Field, Daqing 163000, Heilongjiang, China)

关键词:: 心力衰竭; 肾功能不全; 预防

Keywords:: heart failure; renal dysfunction; prevention

分类号:: R541.6

DOI:: -

文献标识码:: A

摘要:: 肾功能不全与心力衰竭（HF）存在密切关系。25%的慢性HF患者存在肾功能不全。住院的急性HF患者中，64%的患者并发急性肾损害，而这些患者往往都有肾功能不全的病史。如何预防HF患者发生肾功能不全，一直是心内科医师关注的热点问题。近年来，广大心内科医师提出了多种措施预防HF患者的肾功能不全,并获得了一定进展。本文结合最近的相关文献报道，就预防HF患者发生肾功能不全的新认识与研究进展作如下综述。

Abstract:: A close relationship exists between renal dysfunction and heart failure (HF) and 25% of patients with chronic HF are complicated by renal dysfunction. Among the patients with acute HF, 64% are complicated by acute renal damage and these patients often have a history of renal dysfunction. How to prevent renal dysfunction in HF patients is of great research interest for cardiologists. In recent years, cardiologists have offered a variety of measures to prevent renal dysfunction in patients with HF and some progress has been achieved. In this article some new understanding and research progress in the prevention of renal dysfunction in patients with heart failure were reviewed.

参考文献/References

[1]周赟,王骏,王鸣和.心肾综合征诊治进展[J].心血管病学进展,2011,32 (3):377-381.
[2]向文普.多种利尿剂不同给药途径和剂量治疗慢性心力衰竭急性加重期的疗效[J].中国实用医药,2011,6(25):20-22.
[3]Felker GM,Lee KL,Bull DA, et al.Diuretic strategies in patients with acute decompensated heart failure[J].N Engl J Med,2011,364(9):797-805.
[4]欧阳劭，陈伟，匡希斌.培哚普利对自发性高血压大鼠肾脏水通道蛋白 2 的影响[J].中华高血压杂志,2011,19(5):459-463.
[5]杜娟.他汀类药物用于预防和治疗糖尿病多种并发症的研究进展[J].中国临床药学杂志,2011,20(1):58.
[6]Campese VM,Ku E,Bigazzi R.Do HMG-CoA reductase inhibitors improve kidney function? The saga continues[J].J Nephrol,2011,24(5):550-553.
[7]Gissi-HF Investigators,Tavazzi L,Maggioni AP,et al.Effect of rosuvastatin in patients with chronic heart failure(the GISSI-HF trial):a randomised,double-blind,placebo-controlled trial[J].Lancet,2008,372(9645):1231-1239.
[8]Florkowski CM,Molyneux SL,George PM.Rosuvastatin in older patients with systolic heart failure[J].N Engl J Med,2008,358(12):1301.
[9]Liu PP.Cardiorenal syndrome in heart failure:a cardiologist’s perspective[J].Can J Cardiol,2008,24(Suppl B):25B-29B.
[10]Hirsch GA,Bottomley PA,Gerstenblith G,et al.Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts[J].J Am Coll Cardiol,2012,59(9):802-808.
[11]Goicoechea M,Garcia de Vinuesa S,Verdalles U,et al.Effect of allopurinol on chronic kidney disease progression and cardiovascular risk[J].Clin J Am Soc Nephrol,2010, 5(8):1388-1393.
[12]Doehner W,Landmesser U.Xanthine oxidase and uric acid in cardiovascular disease:clinical impact and therapeutic options[J].Semin Nephrol,2011,31(5):433-440.
[13]Persson F,Rossing P,Reinhard H,et al.Renal effects of aliskiren compared with and in combination with inbesartan in patients with type 2 diabetes, hypertension, and albuminuria[J].Diab Care,2009,32(10):1873-1879.
[14]Solomon SD,Shin SH,Shah A,et al.Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction[J].Eur Heart J,2011,32(10):1227-1234.
[15]Krum H,Massie B,Abraham WT,et al.Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE(ATMOSPHERE)study[J].Eur J Heart Fail,2011,13(1):107-114.
[16]Gheorghiade M, Albaghdadi M, Zannad F,et al.Rationale and design of the multicentre, randomized, double-blind, placebocontrolled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)[J].Eur J Heart Fail,2011,13(1):100-106.
[17]Symplicity HTN-2 Investigators,Esler MD,Krum H,et al.Renal sympathetic denervation in patients with treatment-resistanthypertension(the symplicity HTN-2 trial):a randomised controlled trial[J].Lancet,2010,376(9756):1903-1909.
[18]Sobotka PA,Krum H,B?hm M,et al.The role of renal denervation in the treatment of heart failure[J].Curr Cardiol Rep,2012,14(3):285-392.
[19]O’Connor CM,Starling RC,Hernandez AF,et al.Effect of nesiritide in patients with acute decompensated heart failure[J].N Engl J Med,2011,365(1):32-43.

我们的网站为什么显示成这样？

预防心衰患者发生肾功能不全:新认识与研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics